Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor

被引:12
作者
Aljobaily, Nouf [1 ]
Krutsinger, Kelsey [2 ]
Viereckl, Michael J. [2 ]
Joly, Raznin [2 ]
Menlove, Bridger [2 ]
Cone, Brexton [2 ]
Suppes, Ailaina [2 ]
Han, Yuyan [2 ]
机构
[1] Univ Utah, Dept Pathol, Div Microbiol & Immunol, Salt Lake City, UT 84112 USA
[2] Univ Northern Colorado, Dept Biol Sci, Greeley, CO 80639 USA
关键词
non-alcoholic steatohepatitis; non-alcoholic fatty liver disease; cannabigerol; methionine-choline-deficient diet; inflammation; fibrosis; LIVER-DISEASE CURRENT; ANIMAL-MODELS; CB1; RECEPTOR; STEATOHEPATITIS; STEATOSIS; THERAPIES; INSULIN;
D O I
10.3390/nu15010178
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Non-Alcoholic Steatohepatitis (NASH) is the progressive form of Non-Alcoholic Fatty Liver Disease (NAFLD). NASH is distinguished by severe hepatic fibrosis and inflammation. The plant-derived, non-psychotropic compound cannabigerol (CBG) has potential anti-inflammatory effects similar to other cannabinoids. However, the impact of CBG on NASH pathology is still unknown. This study demonstrated the therapeutic potential of CBG in reducing hepatic steatosis, fibrosis, and inflammation. Methods: 8-week-old C57BL/6 male mice were fed with methionine/choline deficient (MCD) diet or control (CTR) diets for five weeks. At the beginning of week 4, mice were divided into three sub-groups and injected with either a vehicle, a low or high dose of CBG for two weeks. Overall health of the mice, Hepatic steatosis, fibrosis, and inflammation were evaluated. Results: Increased liver-to-body weight ratio was observed in mice fed with MCD diet, while a low dose of CBG treatment rescued the liver-to-body weight ratio. Hepatic ballooning and leukocyte infiltration were decreased in MCD mice with a low dose of CBG treatment, whereas the CBG treatment did not change the hepatic steatosis. The high dose CBG administration increased inflammation and fibrosis. Similarly, the expression of cannabinoid receptor (CB)1 and CB2 showed decreased expression with the low CBG dose but not with the high CBG dose intervention in the MCD group and were co-localized with mast cells. Additionally, the decreased mast cells were accompanied by decreased expression of transforming growth factor (TGF)-beta 1. Conclusions: Collectively, the low dose of CBG alleviated hepatic fibrosis and inflammation in MCD-induced NASH, however, the high dose of CBG treatment showed enhanced liver damage when compared to MCD only group. These results will provide pre-clinical data to guide future intervention studies in humans addressing the potential uses of CBG for inflammatory liver pathologies, as well as open the door for further investigation into systemic inflammatory pathologies.
引用
收藏
页数:16
相关论文
共 54 条
[1]   The acute effect of cannabis on plasma, liver and brain ammonia dynamics, a translational study [J].
Abulseoud, Osama A. ;
Zuccoli, Maria Laura ;
Zhang, Lifeng ;
Barnes, Allan ;
Huestis, Marilyn A. ;
Lin, Da-Ting .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 (07) :679-690
[2]  
American Liver Foundation, 2021, NASH CLIN TRIAL OV T
[3]   Cannabigerol Prevents Quorum Sensing and Biofilm Formation of Vibrio harveyi [J].
Aqawi, Muna ;
Gallily, Ruth ;
Sionov, Ronit Vogt ;
Zaks, Batya ;
Friedman, Michael ;
Steinberg, Doron .
FRONTIERS IN MICROBIOLOGY, 2020, 11
[4]   Pharmacological Inhibition of the Chemokine C-C Motif Chemokine Ligand 2 (Monocyte Chemoattractant Protein 1) Accelerates Liver Fibrosis Regression by Suppressing Ly-6C+ Macrophage Infiltration in Mice [J].
Baeck, Christer ;
Wei, Xiao ;
Bartneck, Matthias ;
Fech, Viktor ;
Heymann, Felix ;
Gassler, Nikolaus ;
Hittatiya, Kanishka ;
Eulberg, Dirk ;
Luedde, Tom ;
Trautwein, Christian ;
Tacke, Frank .
HEPATOLOGY, 2014, 59 (03) :1060-1072
[5]   Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease [J].
Borrelli, Francesca ;
Fasolino, Ines ;
Romano, Barbara ;
Capasso, Raffaele ;
Maiello, Francesco ;
Coppola, Diana ;
Orlando, Pierangelo ;
Battista, Giovanni ;
Pagano, Ester ;
Di Marzo, Vincenzo ;
Izzo, Angelo A. .
BIOCHEMICAL PHARMACOLOGY, 2013, 85 (09) :1306-1316
[6]   Current management of NAFLD/NASH [J].
Cardoso, Ana Carolina ;
de Figueiredo-Mendes, Claudio ;
A. Villela-Nogueira, Cristiane .
LIVER INTERNATIONAL, 2021, 41 :89-94
[7]   Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist [J].
Cascio, M. G. ;
Gauson, L. A. ;
Stevenson, L. A. ;
Ross, R. A. ;
Pertwee, R. G. .
BRITISH JOURNAL OF PHARMACOLOGY, 2010, 159 (01) :129-141
[8]   A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease [J].
Chen, Zhonge ;
Yu, Rong ;
Xiong, Ying ;
Du, Fangteng ;
Zhu, Shuishan .
LIPIDS IN HEALTH AND DISEASE, 2017, 16
[9]   Hepatic inflammation and progressive liver fibrosis in chronic liver disease [J].
Czaja, Albert J. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (10) :2515-2532
[10]   A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists [J].
Di Marzo, V .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2006, 27 (03) :134-140